AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28592166
Drug: Continuous bilateral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous bilateral thoracic paravertebral infusion of 0.5% lidocaine (1 mg.kg‐1.hr‐1)
Trial: 28592166
Drug: Subcutaneous infusion
RxNorm normalized name: subcutaneous infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous infusion of lidocaine at the same rate through catheters inserted at the same locations
Trial: 24958605
Drug: CE‐then‐AT +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE‐then‐AT + RT (8 weeks of 'sham' training followed by 8 weeks concurrent aerobic and resistance training)
Trial: 21527575
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (LDX) doses of 30 mg, 50 mg, and 70 mg
Trial: 15084807
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil (CAE) 20 mg/kg/day (max. 500 mg) b.i.d. for 5 days
Trial: 15084807
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V (PenV) 50,000 IU/kg (30 mg/kg) t.i.d. for 10 days
Trial: 26068576
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus Cisplatin with sequential gefitinib (arm B)
Trial: 22190027
Drug: Exercise-induced dehydration
RxNorm normalized name: Dehydrated Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise-induced dehydration with no diuretic (DN)
Trial: 22190027
Drug: Exercise-induced dehydration
RxNorm normalized name: Dehydrated Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise-induced dehydration plus diuretic (DD; furosemide, 40 mg)
Trial: 20704666
Drug: Transforaminal injection
RxNorm normalized name: transforming growth factor beta 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transforaminal injection of steroid
Trial: 20704666
Drug: Transforaminal injection
RxNorm normalized name: transforming growth factor beta 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transforaminal injection of local anesthetic
Trial: 20704666
Drug: Transforaminal injection
RxNorm normalized name: transforming growth factor beta 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transforaminal injection of saline
Trial: 20704666
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of steroid
Trial: 15773400
Drug: Inactivated poliomyelitis
RxNorm normalized name: Inactivated poliomyelitis vaccine (V.C.O.) type 2 MEF1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated poliomyelitis vaccine (IPV) 'Imovax Polio'
Trial: 15773400
Drug: Oral vaccine
RxNorm normalized name: RotaTeq Oral Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vaccine (following IPV)
Trial: 10417577
Drug: Botox injections
RxNorm normalized name: Botox
DrugBank: DaxibotulinumtoxinA (DB17929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botox injections to the glabella, forehead or lateral canthal regions
Trial: 7732714
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg/day (lipid-lowering drug)
Trial: 2277377
Drug: Cefmetazole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefmetazole (1 g intramuscularly preoperatively)
Trial: 2277377
Drug: Cefonicid (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefonicid (1 g intramuscularly preoperatively)
Trial: 17557045
Drug: Empirical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical treatment for extraesophageal manifestations of GER
Trial: 14994324
Drug: Lormetazepam oral
RxNorm normalized name: lormetazepam Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lormetazepam oral solution
Trial: 14994324
Drug: Lormetazepam tablets
DrugBank: Lormetazepam (DB13872)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lormetazepam tablets
Trial: 10197085
Drug: hGH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hGH therapy (0.125U/kg/wk increasing to 0.25U/kg/wk)
Trial: 10197085
Drug: hGH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hGH therapy
Trial: 4042528
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg nicotine base in a 30% aqueous solution
Trial: 4042528
Drug: Inactive placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive placebo solution
Trial: 28965648
Drug: Immediate-release oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release oxycodone with supportive strategies
Trial: 27052743
Drug: Autologous CIK
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous CIK cell immunotherapy in combination with chemotherapy (FOLFOX4 plan)
Trial: 27052743
Drug: Chemotherapy (FOLFOX4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (FOLFOX4 plan) alone
Trial: 25461784
Drug: Technician-administered internet
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technician-administered internet cognitive behaviour therapy (iCBT)
Trial: 22956251
Drug: VBLOC® Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VBLOC® Therapy (vagal blockade)
Trial: 22956251
Drug: VBLOC® Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VBLOC® Therapy (vagal blockade) with ≥ 12 h/day use
Trial: 20202489
Drug: naproxcinod 375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxcinod 375 mg
Trial: 20202489
Drug: naproxcinod 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxcinod 750 mg
Trial: 20202489
Drug: naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen 500 mg
Trial: 17967821
Drug: Late CPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late CPAP (CPAP added to medical treatment for 15 min)
Trial: 8638755
Drug: Standard physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard physical therapy program with patellar taping
Trial: 8638755
Drug: Standard physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard physical therapy program without patellar taping
Trial: 4048835
Drug: Fat (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat (50 g)
Trial: 4048835
Drug: Protein (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein (50 g)
Trial: 4048835
Drug: Starch (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starch (50 g)
Trial: 31204114
Drug: DMPA‐IM (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMPA‐IM (150 mg/mL every 3 months)
Trial: 15194131
Drug: Gatifloxacin 400
RxNorm normalized name: gatifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin 400 mg as a single shot
Trial: 15194131
Drug: Gatifloxacin 200
RxNorm normalized name: gatifloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin 200 mg once daily for 3 days
Trial: 8424511
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of morphine in 25 mL of saline (Group 1)
Trial: 8424511
Drug: 25 mL
RxNorm normalized name: ethanol 6.025 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mL of 0.25% bupivacaine (62.5 mg) (Group 2)
Trial: 8424511
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 5 mg of morphine and 62.5 mg of bupivacaine in 25 mL dilution (Group 3)
Trial: 8424511
Drug: 25 mL
RxNorm normalized name: ethanol 6.025 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mL of saline (Group 4)
Trial: 3318543
Drug: Morphine 33
RxNorm normalized name: morphine sulfate 33 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 33 micrograms/minute
Trial: 29161166
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (motivational element, quitting preparation components, pre-quit nicotine patch)
Trial: 27480840
Drug: Alogliptin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin with ACE inhibitor
Trial: 27480840
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with ACE inhibitor
Trial: 27480840
Drug: Alogliptin without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin without ACE inhibitor
Trial: 27480840
Drug: Placebo without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo without ACE inhibitor
Trial: 27480840
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of ACE inhibitor
Trial: 11912360
Drug: Vehicle saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle saline solution
Trial: 9707351
Drug: (R)-propranolol 80
RxNorm normalized name: propranolol hydrochloride 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (R)-propranolol 80 mg
Trial: 9707351
Drug: (S)-propranolol 80
RxNorm normalized name: propranolol hydrochloride 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (S)-propranolol 80 mg
Trial: 9707351
Drug: rac-propranolol 160
RxNorm normalized name: propranolol hydrochloride 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rac-propranolol 160 mg
Trial: 8520187
Drug: 200‐mg vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200‐mg vaginal progesterone suppositories
Trial: 1669270
Drug: Immunotherapy in
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy in A Group (10 patients)
Trial: 31593588
Drug: CMV gB/MF59
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMV gB/MF59 vaccine
Trial: 28131322
Drug: Dalfampridine extended
RxNorm normalized name: Dalfampridine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalfampridine extended release (D-ER) 10 mg BID
Trial: 21333385
Drug: Intravenous erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous erythromycin infusion without nasogastric tube placement (erythromycin group)
Trial: 21333385
Drug: Intravenous erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous erythromycin infusion combined with nasogastric tube placement (nasogastric-erythromycin group)
Trial: 19892392
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment (Oportunidades programme for 18 months earlier)
Trial: 19892392
Drug: Late treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late treatment (Oportunidades programme started 18 months later)
Trial: 16881772
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of medication management and intensive behavior therapy (Comb)
Trial: 16881772
Drug: Community-treated comparison
RxNorm normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-treated comparison (CC)
Trial: 11339912
Drug: Polymorphism of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymorphism of interleukin‐1 receptor antagonist gene
Trial: 11339912
Drug: Three mutant
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three mutant alleles of interleukin‐1 beta and interleukin‐1 receptor antagonist genes
Trial: 9198829
Drug: Thyroxin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroxin treatment (started on average 5 years after surgery)
Trial: 9198829
Drug: Thyroxin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroxin treatment (permanently treated)
Trial: 9198829
Drug: Thyroxin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroxin treatment (in patients with nodular regrowth)
Trial: 9198829
Drug: Thyroxin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroxin treatment (in patients with high serum TSH concentrations)
Trial: 1586270
Drug: Haloperidol low
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol low dose (2 to 13 ng/mL)
Trial: 1586270
Drug: Haloperidol medium
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol medium dose (13.1 to 24 ng/mL)
Trial: 1586270
Drug: Haloperidol high
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol high dose (24.1 to 35 ng/mL)
Trial: 3894872
Drug: Caffeine solution
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine solution (5 mg X kg‐1 body weight)
Trial: 3894872
Drug: Electrolyte‐glucose solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrolyte‐glucose solution (ERG)
Trial: 28423480
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D3 (20,000 IU)
Trial: 28423480
Drug: Standard-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose vitamin D3 (800 IU)
Trial: 21518220
Drug: Nevirapine (NVP)
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nevirapine (NVP) 200 mg twice daily or 400 mg once daily combined with tenofovir 300 mg/emtricitabine 200 mg once daily
Trial: 21518220
Drug: Atazanavir/ritonavir (ATZ/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir/ritonavir (ATZ/r) 300 mg/100 mg once daily combined with tenofovir 300 mg/emtricitabine 200 mg once daily
Trial: 18350281
Drug: 333 mg
RxNorm normalized name: aspirin 333 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 333 mg Salvia extract
Trial: 18350281
Drug: 167 mg
RxNorm normalized name: silymarin 167 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 167 mg Salvia extract
Trial: 18350281
Drug: 666 mg
RxNorm normalized name: lactulose 666 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 666 mg Salvia extract
Trial: 18350281
Drug: 1332 mg
RxNorm normalized name: imdevimab 1332 MG in 11.1 MG Injection (EUA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1332 mg Salvia extract
Trial: 17068306
Drug: rt-PA (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rt-PA (intravenous recombinant tissue plasminogen activator)
Trial: 14535908
Drug: Remifentanil (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (loading dose 1 microg x kg(‐1); maintenance infusion, 0.25 microg x kg(‐1) min(‐1))
Trial: 14535908
Drug: Alfentanil (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (loading dose 50 microg x kg(‐1); maintenance infusion, 1 microg x kg(‐1) min(‐1))
Trial: 8838433
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg once daily (increased to 10 mg if necessary)
Trial: 8838433
Drug: Diltiazem 90
RxNorm normalized name: diltiazem 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 90 mg twice daily (increased to 180 mg if necessary)
Trial: 3900155
Drug: Placebo (initially)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (initially) then crossed over to 3% topical minoxidil
Trial: 3793950
Drug: Conventional quinidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional quinidine sulfate 300 mg q6h
Trial: 3793950
Drug: Sustained-release quinidine
RxNorm normalized name: quinidine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release quinidine sulfate 600 mg q12h
Trial: 3793950
Drug: Sustained-release quinidine
RxNorm normalized name: quinidine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release quinidine gluconate 648 mg q12h
Trial: 16817580
Drug: Daily activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily activities (sitting, walking, running, jumping jacks, vertical leap, jumping off a step)
Trial: 14570661
Drug: Epidural bolus
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bolus administration of fentanyl (0.03 mg followed by 0.1 mg 210 min later)
Trial: 14570661
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of fentanyl (0.03 mg/h followed by 0.1 mg/hr 210 min later for 200 min)
Trial: 14570661
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of fentanyl
Trial: 14570661
Drug: Epidural bolus
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bolus administration of fentanyl
Trial: 10894961
Drug: Daily repeated
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily repeated applications of moisturizers (twice daily for 5 days)
Trial: 4004715
Drug: Weight-loss treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-loss treatment groups defined by homogeneity (similar gender and degree of overweight)
Trial: 4004715
Drug: Weight-loss treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-loss treatment groups defined by heterogeneity (dissimilar gender and degree of overweight)
Trial: 31699516
Drug: Second generation
RxNorm normalized name: Second generation cephalosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second generation antipsychotics (AP); 92% of patients received this intervention; 74% received AP monotherapy; 79.5% received off-label AP prescriptions.
Trial: 31699516
Drug: First 3
RxNorm normalized name: 3-Step First Aid Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First 3 months of treatment; noted as a significant period for AEs.
Trial: 20837824
Drug: Pioglitazone (Actos),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (Actos), 45 mg daily, plus 200 IU of vitamin E daily
Trial: 20837824
Drug: Placebo, plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, plus 200 IU of vitamin E daily
Trial: 18952945
Drug: Non-interruptive medication
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-interruptive medication laboratory alerts
Trial: 17196292
Drug: Spa Therapy
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spa Therapy (ST)
Trial: 7807701
Drug: Flucytosine (5‐FC)
RxNorm normalized name: Flucytosine
DrugBank: Flucytosine (DB01099)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flucytosine (5‐FC) in combination with fluconazole (FLCZ) at half doses
Trial: 591625
Drug: Oral L-tryptophan
RxNorm normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral L-tryptophan (90 mg/kg BW)
Trial: 23677794
Drug: Brief 3-minute
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief 3-minute drug advice (control; n=161)
Trial: 15071125
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg of torcetrapib daily
Trial: 15071125
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg of torcetrapib twice daily
Trial: 9393430
Drug: Implant designs
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implant designs with higher success rates
Trial: 9393430
Drug: Specific implant
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific implant design
Trial: 8200949
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) low dose (0.4 IU/kg.week)
Trial: 8200949
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) high dose (1.2 IU/kg.week)
Trial: 3147809
Drug: Nifedipine (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10, 20, and 30 mg tid)
Trial: 3147809
Drug: Propranolol (20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (20, 40, and 80 mg tid)
Trial: 21905094
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose vitamin B complex
Trial: 16554289
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg for 3 days followed by ER ciprofloxacin 1000 mg
Trial: 16554289
Drug: ER ciprofloxacin
RxNorm normalized name: ciprofloxacin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ER ciprofloxacin 1000 mg